![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
The agreement with Asembia is an important step for Emmaus, as their team will assist in streamlining the insurance authorization process for Endari as well as deployment of various patient assistance programs.
Lead Product(s): L-Glutamine
Therapeutic Area: Genetic Disease Product Name: Endari
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Emmaus Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 04, 2021